XML 55 R32.htm IDEA: XBRL DOCUMENT
v3.24.3

Segments of Business and Geographic Areas (Tables) | 9 Months Ended
--- | ---
Sep. 29, 2024
Segment Reporting [Abstract] |
Sales By Segment Of Business |
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 29, 2024 |  | October 1, 2023 |  | Percent Change |  | September 29, 2024 |  | October 1, 2023 |  | Percent Change
INNOVATIVE MEDICINE |  |  |  |  |  |  |  |  |  |  |  |
Immunology |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | $3,068 |  | 3,193 |  | (3.9) | % |  | $8,499 |  | 8,506 |  | (0.1) | %
International |  | 1,552 |  | 1,656 |  | (6.2) |  |  | 5,090 |  | 4,951 |  | 2.8 |
Worldwide |  | 4,621 |  | 4,849 |  | (4.7) |  |  | 13,590 |  | 13,457 |  | 1.0 |
REMICADE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 281 |  | 296 |  | (5.4) |  |  | 778 |  | 849 |  | (8.5) |
U.S. Exports |  | 27 |  | 38 |  | (28.9) |  |  | 89 |  | 112 |  | (20.5) |
International |  | 112 |  | 127 |  | (11.5) |  |  | 380 |  | 449 |  | (15.4) |
Worldwide |  | 419 |  | 461 |  | (9.1) |  |  | 1,246 |  | 1,410 |  | (11.6) |
SIMPONI / SIMPONI ARIA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 299 |  | 310 |  | (3.7) |  |  | 820 |  | 866 |  | (5.3) |
International |  | 218 |  | 319 |  | (31.8) |  |  | 787 |  | 829 |  | (5.1) |
Worldwide |  | 516 |  | 629 |  | (18.0) |  |  | 1,607 |  | 1,695 |  | (5.2) |
STELARA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,770 |  | 1,912 |  | (7.5) |  |  | 5,021 |  | 5,180 |  | (3.1) |
International |  | 906 |  | 951 |  | (4.8) |  |  | 2,991 |  | 2,925 |  | 2.2 |
Worldwide |  | 2,676 |  | 2,864 |  | (6.6) |  |  | 8,012 |  | 8,105 |  | (1.2) |
TREMFYA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 691 |  | 634 |  | 9.1 |  |  | 1,789 |  | 1,490 |  | 20.1 |
International |  | 316 |  | 258 |  | 22.6 |  |  | 932 |  | 747 |  | 24.7 |
Worldwide |  | 1,007 |  | 891 |  | 13.0 |  |  | 2,721 |  | 2,237 |  | 21.6 |
OTHER IMMUNOLOGY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1 |  | 2 |  | (45.6) |  | 3 |  | 9 |  | (66.8) |
International |  | 0 |  | 0 |  | — |  |  | 0 |  | 0 |  | —
Worldwide |  | 1 |  | 2 |  | (45.6) |  | 3 |  | 9 |  | (66.8) |
Infectious Diseases |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 365 |  | 360 |  | 1.5 |  |  | 1,023 |  | 1,147 |  | (10.8) |
International |  | 471 |  | 500 |  | (5.7) |  |  | 1,599 |  | 2,420 |  | (33.9) |
Worldwide |  | 836 |  | 859 |  | (2.7) |  |  | 2,622 |  | 3,566 |  | (26.5) |
COVID-19 VACCINE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 0 |  | 0 |  | — |  |  | 0 |  | 0 |  | —
International |  | 1 |  | 41 |  | (97.7) |  |  | 198 |  | 1,073 |  | (81.6) |
Worldwide |  | 1 |  | 41 |  | (97.7) |  |  | 198 |  | 1,073 |  | (81.6) |
EDURANT / rilpivirine |  |  |  |  |  |  |  |  |  |  |  |
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 29, 2024 |  | October 1, 2023 |  | Percent Change |  | September 29, 2024 |  | October 1, 2023 |  | Percent Change
U.S. |  | 8 |  | 9 |  | (15.8) |  |  | 24 |  | 26 |  | (10.0) |
International |  | 323 |  | 287 |  | 12.3 |  |  | 926 |  | 816 |  | 13.5 |
Worldwide |  | 330 |  | 297 |  | 11.5 |  |  | 950 |  | 843 |  | 12.7 |
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 355 |  | 345 |  | 2.8 |  |  | 990 |  | 1,105 |  | (10.5) |
International |  | 94 |  | 102 |  | (6.9) |  |  | 315 |  | 310 |  | 1.8 |
Worldwide |  | 449 |  | 447 |  | 0.6 |  |  | 1,305 |  | 1,415 |  | (7.8) |
OTHER INFECTIOUS DISEASES |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 3 |  | 5 |  | (52.2) |  |  | 10 |  | 15 |  | (37.7) |
International |  | 53 |  | 69 |  | (23.2) |  |  | 160 |  | 220 |  | (27.4) |
Worldwide |  | 55 |  | 74 |  | (25.4) |  |  | 169 |  | 235 |  | (28.0) |
Neuroscience |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,094 |  | 1,036 |  | 5.6 |  |  | 3,250 |  | 3,043 |  | 6.8 |
International |  | 662 |  | 706 |  | (6.2) |  |  | 2,090 |  | 2,296 |  | (8.9) |
Worldwide |  | 1,755 |  | 1,742 |  | 0.8 |  |  | 5,340 |  | 5,339 |  | 0.0
CONCERTA / methylphenidate |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 26 |  | 57 |  | (55.0) |  |  | 101 |  | 191 |  | (47.5) |
International |  | 117 |  | 133 |  | (11.9) |  |  | 382 |  | 412 |  | (7.3) |
Worldwide |  | 142 |  | 189 |  | (24.8) |  |  | 482 |  | 603 |  | (20.0) |
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 780 |  | 730 |  | 6.8 |  |  | 2,329 |  | 2,164 |  | 7.6 |
International |  | 269 |  | 299 |  | (10.1) |  |  | 830 |  | 940 |  | (11.7) |
Worldwide |  | 1,049 |  | 1,029 |  | 1.9 |  |  | 3,159 |  | 3,104 |  | 1.8 |
SPRAVATO |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 243 |  | 154 |  | 56.8 |  |  | 660 |  | 409 |  | 61.2 |
International |  | 42 |  | 29 |  | 44.6 |  |  | 120 |  | 74 |  | 62.9 |
Worldwide |  | 284 |  | 183 |  | 54.9 |  |  | 780 |  | 483 |  | 61.5 |
OTHER NEUROSCIENCE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 46 |  | 94 |  | (51.4) |  |  | 161 |  | 278 |  | (42.1) |
International |  | 235 |  | 245 |  | (4.4) |  |  | 759 |  | 870 |  | (12.8) |
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 29, 2024 |  | October 1, 2023 |  | Percent Change |  | September 29, 2024 |  | October 1, 2023 |  | Percent Change
Worldwide |  | 281 |  | 340 |  | (17.4) |  |  | 920 |  | 1,149 |  | (19.9) |
Oncology |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,816 |  | 2,219 |  | 26.9 |  |  | 7,835 |  | 6,177 |  | 26.8 |
International |  | 2,565 |  | 2,313 |  | 10.9 |  |  | 7,450 |  | 6,865 |  | 8.5 |
Worldwide |  | 5,380 |  | 4,533 |  | 18.7 |  |  | 15,284 |  | 13,043 |  | 17.2 |
CARVYKTI |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 258 |  | 140 |  | 84.9 |  |  | 565 |  | 324 |  | 74.6 |
International |  | 27 |  | 12 |  | * |  | 63 |  | 17 |  | *
Worldwide |  | 286 |  | 152 |  | 87.7 |  |  | 629 |  | 341 |  | 84.3 |
DARZALEX |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,684 |  | 1,369 |  | 23.0 |  |  | 4,789 |  | 3,882 |  | 23.4 |
International |  | 1,332 |  | 1,130 |  | 17.9 |  |  | 3,797 |  | 3,312 |  | 14.6 |
Worldwide |  | 3,016 |  | 2,499 |  | 20.7 |  |  | 8,586 |  | 7,194 |  | 19.3 |
ERLEADA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 337 |  | 288 |  | 17.1 |  |  | 940 |  | 778 |  | 20.8 |
International |  | 453 |  | 342 |  | 32.4 |  |  | 1,275 |  | 961 |  | 32.6 |
Worldwide |  | 790 |  | 631 |  | 25.4 |  |  | 2,215 |  | 1,740 |  | 27.3 |
IMBRUVICA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 259 |  | 264 |  | (1.9) |  |  | 770 |  | 796 |  | (3.2) |
International |  | 494 |  | 545 |  | (9.2) |  |  | 1,537 |  | 1,681 |  | (8.5) |
Worldwide |  | 753 |  | 808 |  | (6.8) |  |  | 2,307 |  | 2,476 |  | (6.8) |
TECVAYLI |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 105 |  | 93 |  | 13.5 |  |  | 310 |  | 232 |  | 34.0 |
International |  | 30 |  | 19 |  | 54.2 |  |  | 93 |  | 37 |  | *
Worldwide |  | 135 |  | 112 |  | 20.6 |  |  | 403 |  | 269 |  | 49.6 |
ZYTIGA / abiraterone acetate |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 5 |  | 16 |  | (66.0) |  |  | 25 |  | 41 |  | (38.0) |
International |  | 144 |  | 199 |  | (27.1) |  |  | 470 |  | 646 |  | (27.1) |
Worldwide |  | 150 |  | 214 |  | (30.0) |  |  | 496 |  | 686 |  | (27.8) |
OTHER ONCOLOGY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 168 |  | 50 |  | * |  | 435 |  | 125 |  | *
International |  | 83 |  | 67 |  | 24.8 |  |  | 214 |  | 211 |  | 2.0 |
Worldwide |  | 250 |  | 117 |  | * |  | 649 |  | 336 |  | 93.4 |
Pulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 815 |  | 680 |  | 20.0 |  |  | 2,324 |  | 1,964 |  | 18.4 |
International |  | 287 |  | 274 |  | 4.5 |  |  | 866 |  | 835 |  | 3.7 |
Worldwide |  | 1,102 |  | 954 |  | 15.6 |  |  | 3,190 |  | 2,798 |  | 14.0 |
OPSUMIT |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 406 |  | 323 |  | 25.4 |  |  | 1,135 |  | 924 |  | 22.8 |
International |  | 165 |  | 166 |  | (0.2) |  |  | 504 |  | 512 |  | (1.6) |
Worldwide |  | 571 |  | 490 |  | 16.8 |  |  | 1,639 |  | 1,437 |  | 14.1 |
UPTRAVI |  |  |  |  |  |  |  |  |  |  |  |
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 29, 2024 |  | October 1, 2023 |  | Percent Change |  | September 29, 2024 |  | October 1, 2023 |  | Percent Change
U.S. |  | 379 |  | 336 |  | 12.7 |  |  | 1,120 |  | 978 |  | 14.5 |
International |  | 80 |  | 66 |  | 21.8 |  |  | 232 |  | 185 |  | 25.5 |
Worldwide |  | 458 |  | 402 |  | 14.2 |  |  | 1,352 |  | 1,163 |  | 16.3 |
OTHER PULMONARY HYPERTENSION |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 32 |  | 20 |  | 54.0 |  |  | 70 |  | 61 |  | 14.0 |
International |  | 40 |  | 42 |  | (3.9) |  |  | 129 |  | 137 |  | (5.8) |
Worldwide |  | 72 |  | 63 |  | 15.0 |  |  | 199 |  | 199 |  | 0.3 |
Cardiovascular / Metabolism / Other |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 713 |  | 763 |  | (6.5) |  |  | 2,061 |  | 2,254 |  | (8.5) |
International |  | 170 |  | 194 |  | (11.9) |  |  | 543 |  | 580 |  | (6.4) |
Worldwide |  | 884 |  | 957 |  | (7.6) |  |  | 2,605 |  | 2,834 |  | (8.1) |
XARELTO |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 592 |  | 625 |  | (5.2) |  |  | 1,697 |  | 1,840 |  | (7.8) |
International |  | — |  | — |  | — |  |  | — |  | — |  | — |
Worldwide |  | 592 |  | 625 |  | (5.2) |  |  | 1,697 |  | 1,840 |  | (7.8) |
OTHER |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 121 |  | 139 |  | (12.2) |  |  | 364 |  | 414 |  | (11.9) |
International |  | 170 |  | 194 |  | (11.9) |  |  | 543 |  | 580 |  | (6.4) |
Worldwide |  | 292 |  | 332 |  | (12.0) |  |  | 908 |  | 994 |  | (8.7) |
TOTAL INNOVATIVE MEDICINE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 8,871 |  | 8,249 |  | 7.5 |  |  | 24,993 |  | 23,090 |  | 8.2 |
International |  | 5,709 |  | 5,644 |  | 1.2 |  |  | 17,639 |  | 17,947 |  | (1.7) |
Worldwide |  | 14,580 |  | 13,893 |  | 4.9 |  |  | 42,632 |  | 41,037 |  | 3.9 |
MEDTECH |  |  |  |  |  |  |  |  |  |  |  |
Cardiovascular(1) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,148 |  | 891 |  | 28.6 |  |  | 3,292 |  | 2,662 |  | 23.6 |
International |  | 819 |  | 667 |  | 22.8 |  |  | 2,353 |  | 2,019 |  | 16.5 |
Worldwide |  | 1,966 |  | 1,558 |  | 26.2 |  |  | 5,645 |  | 4,681 |  | 20.6 |
ELECTROPHYSIOLOGY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 660 |  | 611 |  | 7.9 |  |  | 2,057 |  | 1,791 |  | 14.8 |
International |  | 619 |  | 549 |  | 12.7 |  |  | 1,889 |  | 1,658 |  | 14.0 |
Worldwide |  | 1,279 |  | 1,161 |  | 10.2 |  |  | 3,946 |  | 3,449 |  | 14.4 |
ABIOMED |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 293 |  | 254 |  | 15.4 |  |  | 905 |  | 790 |  | 14.5 |
International |  | 68 |  | 57 |  | 20.1 |  |  | 207 |  | 176 |  | 17.7 |
Worldwide |  | 362 |  | 311 |  | 16.3 |  |  | 1,112 |  | 966 |  | 15.1 |
SHOCKWAVE(2) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 163 |  | — |  | * |  | 240 |  | — |  | *
International |  | 66 |  | — |  | * |  | 66 |  | — |  | *
Worldwide |  | 229 |  | — |  | * |  | 306 |  | — |  | *
OTHER CARDIOVASCULAR(1) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 30 |  | 26 |  | 16.7 |  |  | 89 |  | 81 |  | 10.6 |
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 29, 2024 |  | October 1, 2023 |  | Percent Change |  | September 29, 2024 |  | October 1, 2023 |  | Percent Change
International |  | 66 |  | 61 |  | 7.7 |  |  | 192 |  | 186 |  | 3.0 |
Worldwide |  | 96 |  | 87 |  | 10.4 |  |  | 281 |  | 267 |  | 5.3 |
Orthopaedics |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,359 |  | 1,349 |  | 0.7 |  |  | 4,229 |  | 4,100 |  | 3.2 |
International |  | 832 |  | 815 |  | 2.0 |  |  | 2,614 |  | 2,574 |  | 1.5 |
Worldwide |  | 2,191 |  | 2,164 |  | 1.2 |  |  | 6,843 |  | 6,674 |  | 2.5 |
HIPS |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 250 |  | 239 |  | 4.8 |  |  | 785 |  | 730 |  | 7.5 |
International |  | 131 |  | 136 |  | (3.6) |  |  | 435 |  | 432 |  | 0.6 |
Worldwide |  | 381 |  | 375 |  | 1.7 |  |  | 1,220 |  | 1,162 |  | 5.0 |
KNEES |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 212 |  | 207 |  | 2.2 |  |  | 684 |  | 654 |  | 4.5 |
International |  | 140 |  | 131 |  | 6.9 |  |  | 463 |  | 415 |  | 11.5 |
Worldwide |  | 352 |  | 338 |  | 4.0 |  |  | 1,147 |  | 1,069 |  | 7.2 |
TRAUMA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 497 |  | 488 |  | 1.8 |  |  | 1,499 |  | 1,462 |  | 2.5 |
International |  | 265 |  | 253 |  | 4.2 |  |  | 786 |  | 775 |  | 1.4 |
Worldwide |  | 761 |  | 742 |  | 2.6 |  |  | 2,285 |  | 2,238 |  | 2.1 |
SPINE, SPORTS & OTHER |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 400 |  | 415 |  | (3.6) |  |  | 1,262 |  | 1,254 |  | 0.6 |
International |  | 296 |  | 295 |  | 0.4 |  |  | 930 |  | 952 |  | (2.3) |
Worldwide |  | 696 |  | 710 |  | (1.9) |  |  | 2,191 |  | 2,205 |  | (0.6) |
Surgery |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 983 |  | 994 |  | (1.1) |  |  | 2,965 |  | 2,984 |  | (0.6) |
International |  | 1,451 |  | 1,483 |  | (2.2) |  |  | 4,373 |  | 4,522 |  | (3.3) |
Worldwide |  | 2,434 |  | 2,479 |  | (1.8) |  |  | 7,338 |  | 7,507 |  | (2.2) |
ADVANCED |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 448 |  | 455 |  | (1.4) |  |  | 1,360 |  | 1,365 |  | (0.4) |
International |  | 661 |  | 709 |  | (6.8) |  |  | 1,977 |  | 2,139 |  | (7.6) |
Worldwide |  | 1,109 |  | 1,164 |  | (4.7) |  |  | 3,337 |  | 3,504 |  | (4.8) |
GENERAL |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 535 |  | 540 |  | (0.9) |  |  | 1,605 |  | 1,619 |  | (0.9) |
International |  | 791 |  | 775 |  | 2.1 |  |  | 2,397 |  | 2,383 |  | 0.6 |
Worldwide |  | 1,325 |  | 1,314 |  | 0.8 |  |  | 4,001 |  | 4,002 |  | 0.0
Vision |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 549 |  | 512 |  | 7.2 |  |  | 1,619 |  | 1,599 |  | 1.3 |
International |  | 751 |  | 744 |  | 0.9 |  |  | 2,224 |  | 2,265 |  | (1.8) |
Worldwide |  | 1,300 |  | 1,256 |  | 3.5 |  |  | 3,843 |  | 3,864 |  | (0.5) |
CONTACT LENSES / OTHER |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 441 |  | 399 |  | 10.2 |  |  | 1,288 |  | 1,252 |  | 2.8 |
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 29, 2024 |  | October 1, 2023 |  | Percent Change |  | September 29, 2024 |  | October 1, 2023 |  | Percent Change
International |  | 527 |  | 529 |  | (0.3) |  |  | 1,508 |  | 1,568 |  | (3.8) |
Worldwide |  | 968 |  | 928 |  | 4.2 |  |  | 2,796 |  | 2,820 |  | (0.9) |
SURGICAL |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 108 |  | 112 |  | (3.6) |  |  | 331 |  | 346 |  | (4.4) |
International |  | 225 |  | 216 |  | 3.9 |  |  | 717 |  | 698 |  | 2.7 |
Worldwide |  | 333 |  | 328 |  | 1.3 |  |  | 1,048 |  | 1,044 |  | 0.3 |
TOTAL MEDTECH |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 4,038 |  | 3,747 |  | 7.8 |  |  | 12,105 |  | 11,345 |  | 6.7 |
International |  | 3,853 |  | 3,711 |  | 3.9 |  |  | 11,564 |  | 11,382 |  | 1.6 |
Worldwide |  | 7,891 |  | 7,458 |  | 5.8 |  |  | 23,669 |  | 22,727 |  | 4.1 |
WORLDWIDE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 12,909 |  | 11,996 |  | 7.6 |  |  | 37,098 |  | 34,435 |  | 7.7 |
International |  | 9,562 |  | 9,355 |  | 2.2 |  |  | 29,203 |  | 29,329 |  | (0.4) |
Worldwide |  | $22,471 |  | 21,351 |  | 5.2 | % |  | $66,301 |  | 63,764 |  | 4.0 | %
* Percentage greater than 100% or not meaningful (1) Previously referred to as Interventional Solutions (2) Acquired on May 31, 2024
Operating Profit by Segment of Business |
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended |
(Dollars in Millions) |  | September 29, 2024 |  | October 1, 2023 |  | Percent Change |  | September 29, 2024 |  | October 1, 2023 |  | Percent Change |  |  |  |  |
Innovative Medicine(1) |  | $4,482 |  | 4,794 |  | (6.5) | % |  | $14,910 |  | 14,008 |  | 6.4 | % |  |  |  |  |
MedTech(2) |  | 1,059 |  | 1,185 |  | (10.6) |  |  | 3,668 |  | 4,265 |  | (14.0) |  |  |  |  |  |
Segment earnings before provision for taxes |  | 5,541 |  | 5,979 |  | (7.3) |  |  | 18,578 |  | 18,273 |  | 1.7 |  |  |  |  |  |
Less: Expense not allocated to segments (3) |  | 2,203 |  | 762 |  |  |  | 5,778 |  | 8,037 |  |  |  |  |  |  |
Worldwide income (loss) before tax |  | $3,338 |  | 5,217 |  | (36.0) | % |  | $12,800 |  | 10,236 |  | 25.0 | % |  |  |  |  |
(1) Innovative Medicine includes: •Intangible amortization expense of $0.7 billion in both the fiscal third quarter of 2024 and 2023. Intangible amortization expense of $2.1 billion and $2.2 billion in the fiscal nine months of 2024 and 2023, respectively. •Expense of $1.25 billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition) in the fiscal third quarter and fiscal nine months of 2024. •One-time COVID-19 Vaccine related exit costs of $0.1 billion and $0.7 billion in the fiscal nine months of 2024 and 2023, respectively. •Monetization of royalty rights of $0.3 billion in the fiscal third quarter and fiscal nine months of 2024. •A restructuring related charge of $0.1 billion in the fiscal nine months of 2024. A restructuring related charge of $0.1 billion and $0.4 billion in the fiscal third quarter and fiscal nine months of 2023, respectively. Refer to Note 12 for additional details. •An In-process research and development impairment of $0.2 billion in the fiscal nine months of 2024 and $0.2 billion in the fiscal third quarter and fiscal nine months of 2023 associated with the M710 (biosimilar) asset acquired as part of the acquisition of Momenta Pharmaceuticals in 2020. •Unfavorable changes in the fair value of securities of $0.4 billion and $0.5 billion in the fiscal third quarter and fiscal nine months of 2023, respectively. •Litigation expense of $0.4 billion in both the fiscal third quarter and fiscal nine months of 2024, primarily related to Risperdal Gynecomastia. Favorable litigation related items of $0.1 billion in the fiscal nine months of 2023. (2) MedTech includes: •Intangible amortization expense of $0.5 billion and $0.4 billion in the fiscal third quarter of 2024 and 2023, respectively. Intangible amortization expense of $1.3 billion and $1.1 billion in the fiscal nine months of 2024 and 2023, respectively. •Acquisition and integration related expense of $0.3 billion and $0.9 billion, primarily driven by the Shockwave acquisition, in the fiscal third quarter and fiscal nine months of 2024, respectively. Acquisition and integration related expense of $0.1 billion in the fiscal nine months of 2023. •A gain of $0.2 billion related to the Acclarent divestiture is included in the fiscal nine months of 2024. •A restructuring related charge of $0.1 billion in the fiscal nine months of 2024. A restructuring related charge of $0.2 billion in the fiscal third quarter and fiscal nine months of 2023, respectively. (3) Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal third quarter of 2024 includes charges for talc matters of $2.0 billion. The fiscal nine months of 2024 and 2023 include charges for talc matters of approximately $5.1 billion and $7.0 billion, respectively (See Note 11, Legal Proceedings, for additional details). The fiscal nine months of 2024 includes a loss of approximately $0.4 billion related to the debt to equity exchange of the Company's remaining shares of Kenvue Common Stock. The fiscal third quarter and fiscal nine months of 2023 include $0.6 billion related to the unfavorable change in the fair value of Kenvue shares.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas |
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 29, 2024 |  | October 1, 2023 |  | Percent Change |  | September 29, 2024 |  | October 1, 2023 |  | Percent Change
United States |  | $12,909 |  | 11,996 |  | 7.6 | % |  | $37,098 |  | 34,435 |  | 7.7 | %
Europe |  | 4,914 |  | 4,727 |  | 4.0 |  |  | 15,291 |  | 15,448 |  | (1.0) |
Western Hemisphere, excluding U.S. |  | 1,173 |  | 1,171 |  | 0.3 |  |  | 3,579 |  | 3,383 |  | 5.8 |
Asia-Pacific, Africa |  | 3,475 |  | 3,457 |  | 0.5 |  |  | 10,333 |  | 10,498 |  | (1.6) |
Total |  | $22,471 |  | 21,351 |  | 5.2 | % |  | $66,301 |  | 63,764 |  | 4.0 | %

X
- Definition Sales by segment of business. + References No definition available. + Details
Name: | jnj_SalesBySegmentOfBusinessTableTextBlock
Namespace Prefix: | jnj_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration